|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allen JE and El-Deiry WS: Regulation of
the human TRAIL gene. Cancer Biol Ther. 13:1143–1151. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morales JC, Ruiz-Magaña MJ and Ruiz-Ruiz
C: Regulation of the resistance to TRAIL-induced apoptosis in human
primary T lymphocytes: Role of NF-kappaB inhibition. Mol Immunol.
44:2587–2597. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim YS, Schwabe RF, Qian T, Lemasters JJ
and Brenner DA: TRAIL-mediated apoptosis requires NF-kappaB
inhibition and the mitochondrial permeability transition in human
hepatoma cells. Hepatology. 36:1498–1508. 2002.PubMed/NCBI
|
|
6
|
Keane MM, Rubinstein Y, Cuello M,
Ettenberg SA, Banerjee P, Nau MM and Lipkowitz S: Inhibition of
NF-kappaB activity enhances TRAIL mediated apoptosis in breast
cancer cell lines. Breast Cancer Res Treat. 64:211–219. 2000.
View Article : Google Scholar
|
|
7
|
Jani TS, DeVecchio J, Mazumdar T, Agyeman
A and Houghton JA: Inhibition of NF-kappaB signaling by quinacrine
is cytotoxic to human colon carcinoma cell lines and is synergistic
in combination with tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem.
285:19162–19172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ozören N and El-Deiry WS: Defining
characteristics of types I and II apoptotic cells in response to
TRAIL. Neoplasia. 4:551–557. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stuckey DW and Shah K: TRAIL on trial:
Preclinical advances in cancer therapy. Trends Mol Med. 19:685–694.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gonzalvez F and Ashkenazi A: New insights
into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29:4752–4765.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Voelkel-Johnson C: TRAIL-mediated
signaling in prostate, bladder and renal cancer. Nat Rev Urol.
8:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen C, Edelstein LC and Gélinas C: The
Rel/NF-kappaB family directly activates expression of the apoptosis
inhibitor Bcl-x(L). Mol Cell Biol. 20:2687–2695. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo W, Yu WD, Ma Y, Chernov M, Trump DL
and Johnson CS: Inhibition of protein kinase CK2 reduces Cyp24a1
expression and enhances 1,25-dihydroxyvitamin D(3) antitumor
activity in human prostate cancer cells. Cancer Res. 73:2289–2297.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Agarwal M, Nitta RT and Li G: Casein
kinase 2: A novel player in glioblastoma therapy and cancer stem
cells. J Mol Genet Med. 8:82013.
|
|
15
|
Wang G, Ahmad KA and Ahmed K: Role of
protein kinase CK2 in the regulation of tumor necrosis
factor-related apoptosis inducing ligand-induced apoptosis in
prostate cancer cells. Cancer Res. 66:2242–2249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Orzechowska E, Kozłowska E, Staroń K and
Trzcińska-Danielewicz J: Time schedule-dependent effect of the CK2
inhibitor TBB on PC-3 human prostate cancer cell viability. Oncol
Rep. 27:281–285. 2012.
|
|
17
|
Chen S, Bohrer LR, Rai AN, Pan Y, Gan L,
Zhou X, Bagchi A, Simon JA and Huang H: Cyclin-dependent kinases
regulate epigenetic gene silencing through phosphorylation of EZH2.
Nat Cell Biol. 12:1108–1114. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Silva L, Oh HS, Chang L, Yan Z,
Triezenberg SJ and Knipe DM: Roles of the nuclear lamina in stable
nuclear association and assembly of a herpesviral transactivator
complex on viral immediate-early genes. MBio. 3:e00300–e00311.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Ma J, Wu Z, Li W, Zhang D, Han L,
Wang F, Reindl KM, Wu E and Ma Q: Arginine deiminase augments the
chemosensitivity of argininosuccinate synthetase-deficient
pancreatic cancer cells to gemcitabine via inhibition of NF-κB
signaling. BMC Cancer. 14:6862014. View Article : Google Scholar
|
|
20
|
Hu J, Nakano H, Sakurai H and Colburn NH:
Insufficient p65 phosphorylation at S536 specifically contributes
to the lack of NF-kappaB activation and transformation in resistant
JB6 cells. Carcinogenesis. 25:1991–2003. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harikumar KB, Kunnumakkara AB, Ahn KS,
Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the
cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by
xanthohumol leads to suppression of NF-kappaB-regulated gene
products and potentiation of apoptosis in leukemia cells. Blood.
113:2003–2013. 2009. View Article : Google Scholar
|
|
22
|
Kim HR, Kim K, Lee KH, Kim SJ and Kim J:
Inhibition of casein kinase 2 enhances the death ligand- and
natural killer cell-induced hepatocellular carcinoma cell death.
Clin Exp Immunol. 152:336–344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llobet D, Eritja N, Encinas M, Llecha N,
Yeramian A, Pallares J, Sorolla A, Gonzalez-Tallada FJ, Matias-Guiu
X and Dolcet X: CK2 controls TRAIL and Fas sensitivity by
regulating FLIP levels in endometrial carcinoma cells. Oncogene.
27:2513–2524. 2008. View Article : Google Scholar
|
|
24
|
Hundsdörfer C, Hemmerling HJ, Hamberger J,
Le Borgne M, Bednarski P, Götz C, Totzke F and Jose J: Novel
indeno[1,2-b] indoloquinones as inhibitors of the human protein
kinase CK2 with antiproliferative activity towards a broad panel of
cancer cell lines. Biochem Biophys Res Commun. 424:71–75. 2012.
View Article : Google Scholar
|
|
25
|
Wang G, Ahmad KA, Unger G, Slaton JW and
Ahmed K: CK2 signaling in androgen-dependent and -independent
prostate cancer. J Cell Biochem. 99:382–391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tong L, Yuan Y and Wu S: Therapeutic
microRNAs targeting the NF-kappa B signaling circuits of cancers.
Adv Drug Deliv Rev. 81:1–15. 2015. View Article : Google Scholar
|
|
27
|
Jin R, Yamashita H, Yu X, Wang J, Franco
OE, Wang Y, Hayward SW and Matusik RJ: Inhibition of NF-kappa B
signaling restores responsiveness of castrate-resistant prostate
cancer cells to anti-androgen treatment by decreasing androgen
receptor-variant expression. Oncogene. Sep 15–2014.(Epub ahead of
print).http://dx.doi.org/10.1038/onc.2014.302.
|
|
28
|
Eddy SF, Guo S, Demicco EG, Romieu-Mourez
R, Landesman-Bollag E, Seldin DC and Sonenshein GE: Inducible
IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2
and promotes aberrant nuclear factor-kappaB activation in breast
cancer cells. Cancer Res. 65:11375–11383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Manni S, Brancalion A, Mandato E, Tubi LQ,
Colpo A, Pizzi M, Cappellesso R, Zaffino F, Di Maggio SA, Cabrelle
A, et al: Protein kinase CK2 inhibition down modulates the NF-κB
and STAT3 survival pathways, enhances the cellular proteotoxic
stress and synergistically boosts the cytotoxic effect of
bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS
One. 8:e752802013. View Article : Google Scholar
|
|
30
|
Kim KJ, Cho KD, Jang KY, Kim HA, Kim HK,
Lee HK and Im SY: Platelet-activating factor enhances tumour
metastasis via the reactive oxygen species-dependent protein kinase
casein kinase 2-mediated nuclear factor-κB activation. Immunology.
143:21–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Douillette A, Bibeau-Poirier A, Gravel SP,
Clément JF, Chénard V, Moreau P and Servant MJ: The proinflammatory
actions of angiotensin II are dependent on p65 phosphorylation by
the IkappaB kinase complex. J Biol Chem. 281:13275–13284. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gutierrez H, O'Keeffe GW, Gavaldà N,
Gallagher D and Davies AM: Nuclear factor kappa B signaling either
stimulates or inhibits neurite growth depending on the
phosphorylation status of p65/RelA. J Neurosci. 28:8246–8256. 2008.
View Article : Google Scholar : PubMed/NCBI
|
